Key Takeaways
- Procter & Gamble (PG) announced a $3.8 billion acquisition of premium wellness brand Thorne to bolster its health and supplements portfolio.
- The Atlanta Fed’s GDPNow model revised its Q3 2026 growth estimate down to 5.86% from a previous 6.18%.
- Moderna (MRNA) initiated a Phase 1 clinical trial in Canada for mRNA-1469, a vaccine targeting the Bundibugyo ebolavirus.
- Nvidia (NVDA) and DDN partnered to launch new GPU-driven data access technology aimed at accelerating next-generation AI workloads.
- European equity markets closed higher, led by Germany's DAX, which gained 0.85% on Tuesday.
Corporate M&A and Partnerships
Procter & Gamble (PG) CEO Shailesh Jejurikar confirmed in a CNBC interview that the consumer goods giant will acquire Thorne, a high-end wellness and supplements brand, for $3.8 billion. Jejurikar described Thorne as a "premium wellness" asset that aligns with the company's strategy to expand its footprint in the rapidly growing health sector. The deal is expected to be formally announced later today, marking a significant move for P&G's healthcare division.
In the technology sector, Nvidia (NVDA) and DDN announced a collaboration to enhance GPU-driven data access. The partnership aims to optimize how GPUs interact with massive datasets, reducing latency for next-generation AI applications. By streamlining data movement, the companies intend to maximize the efficiency of AI infrastructure for enterprise customers.
Economic Indicators and Global Markets
The Atlanta Fed's GDPNow model updated its tracking estimate for third-quarter 2026 real GDP growth to 5.86%, down from the 6.18% projected on August 3. Despite the slight downward revision, the figure remains exceptionally high, reflecting robust underlying economic momentum. Market participants are closely watching these "nowcasts" as a real-time gauge of U.S. economic health ahead of official government data.
European markets showed broad strength during Tuesday's session. Germany's DAX outperformed its peers with a 0.85% rise, while France's CAC 40 and Spain's IBEX climbed 0.52% and 0.38%, respectively. Britain's FTSE 100 lagged slightly but still managed a 0.3% gain as investors digested a mix of corporate earnings and geopolitical developments.
Healthcare and Commodities
Moderna (MRNA) has officially started a Phase 1 clinical trial for mRNA-1469 in Canada. The vaccine is designed to combat the Bundibugyo ebolavirus, a rare strain for which no licensed vaccine currently exists. This trial is part of a broader partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million to support the development and manufacturing of the candidate.
In the commodities market, the Global Dairy Trade (GDT) Price Index saw a marginal increase of 0.1% in the latest auction, with the average winning price reaching $3,778 per metric ton. Meanwhile, geopolitical tensions in the Middle East remain in focus as Iran and Oman reportedly entered a new phase of talks regarding a shipping corridor in the Strait of Hormuz. While an agreement is said to be "within reach," Iranian officials continue to cite U.S. obstruction as a primary hurdle to finalizing the deal.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.